| Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials M Khunger, S Rakshit, V Pasupuleti, AV Hernandez, P Mazzone, ... Chest 152 (2), 271-281, 2017 | 432 | 2017 |
| Dose–response relationship between physical activity and risk of heart failure: a meta-analysis A Pandey, S Garg, M Khunger, D Darden, C Ayers, DJ Kumbhani, ... Circulation 132 (19), 1786-1794, 2015 | 314 | 2015 |
| A content analysis of smartphone–based applications for hypertension management N Kumar, M Khunger, A Gupta, N Garg Journal of the American Society of Hypertension 9 (2), 130-136, 2015 | 227 | 2015 |
| Efficacy and safety of exercise training in chronic pulmonary hypertension: systematic review and meta-analysis A Pandey, S Garg, M Khunger, S Garg, DJ Kumbhani, KM Chin, JD Berry Circulation: Heart Failure 8 (6), 1032-1043, 2015 | 140 | 2015 |
| Optimal management of hereditary hemorrhagic telangiectasia N Garg, M Khunger, A Gupta, N Kumar Journal of Blood Medicine, 191-206, 2014 | 136 | 2014 |
| Programmed cell death 1 (PD-1) ligand (PD-L1) expression in solid tumors as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors: a systematic review and meta-analysis M Khunger, AV Hernandez, V Pasupuleti, S Rakshit, NA Pennell, ... JCO Precision Oncology 1, 1-15, 2017 | 128 | 2017 |
| Combination of peri-and intratumoral radiomic features on baseline CT scans predicts response to chemotherapy in lung adenocarcinoma M Khorrami, M Khunger, A Zagouras, P Patil, R Thawani, K Bera, P Rajiah, ... Radiology: Artificial Intelligence 1 (2), 180012, 2019 | 86 | 2019 |
| Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience A Khunger, M Khunger, V Velcheti Therapeutic advances in respiratory disease 12, 1753466618767611, 2018 | 80 | 2018 |
| Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients M Khunger, PD Patil, A Khunger, M Li, B Hu, S Rakshit, A Basu, N Pennell, ... PloS one 13 (10), e0197743, 2018 | 64 | 2018 |
| Safety and efficacy of PD-1/PD-L1 inhibitors in treatment-naive and chemotherapy-refractory patients with non–small-cell lung cancer: a systematic review and meta-analysis M Khunger, P Jain, S Rakshit, V Pasupuleti, AV Hernandez, J Stevenson, ... Clinical lung cancer 19 (3), e335-e348, 2018 | 61 | 2018 |
| Evaluation of CROSS technique with 100% TCA in the management of ice pick acne scars in darker skin types N Khunger, D Bhardwaj, M Khunger Journal of Cosmetic Dermatology 10 (1), 51-57, 2011 | 55 | 2011 |
| Incidence of thromboembolic complications within 30 days of electrical cardioversion performed within 48 hours of atrial fibrillation onset A Garg, M Khunger, S Seicean, MK Chung, PJ Tchou JACC: Clinical Electrophysiology 2 (4), 487-494, 2016 | 52 | 2016 |
| Subcision for depressed facial scars made easy using a simple modification N Khunger, M Khunger Dermatologic Surgery 37 (4), 514-517, 2011 | 33 | 2011 |
| Infection in autoimmune bullous diseases: a retrospective comparative study JS Lehman, M Khunger, CM Lohse The Journal of Dermatology 40 (8), 613-619, 2013 | 32 | 2013 |
| FRMD4A/RET: A novel RET oncogenic fusion variant in non–small cell lung carcinoma V Velcheti, R Thawani, M Khunger, S Mukhopadhyay, DJ Chute, ... Journal of Thoracic Oncology 12 (2), e15-e16, 2017 | 22 | 2017 |
| Premature clinical trial discontinuation in the era of immune checkpoint inhibitors M Khunger, S Rakshit, AV Hernandez, V Pasupuleti, K Glass, MD Galsky, ... The Oncologist 23 (12), 1494-1499, 2018 | 19 | 2018 |
| A case of a patient with idiopathic pulmonary fibrosis with lung squamous cell carcinoma treated with nivolumab M Khunger, V Velcheti Journal of Thoracic Oncology 12 (7), e96-e97, 2017 | 19 | 2017 |
| Computer-extracted features relating to spatial arrangement of tumor infiltrating lymphocytes to predict response to nivolumab in non-small cell lung cancer (NSCLC). C Barrera, P Velu, K Bera, X Wang, P Prasanna, M Khunger, A Khunger, ... Journal of Clinical Oncology 36 (15_suppl), 12115-12115, 2018 | 14 | 2018 |
| Computer extracted features of cancer nuclei from H&E stained tissues of tumor predicts response to nivolumab in non-small cell lung cancer. X Wang, C Barrera, P Velu, K Bera, P Prasanna, M Khunger, A Khunger, ... Journal of Clinical Oncology 36 (15_suppl), 12061-12061, 2018 | 10 | 2018 |
| Pre-treatment hematological markers as a predictive biomarker for survival in patients with non-small cell lung cancer treated with nivolumab. PD Patil, M Khunger, S Rakshit, J Stevenson, NA Pennell, P Elson, ... Journal of Clinical Oncology 35 (15_suppl), 11547-11547, 2017 | 10 | 2017 |
